Background: A sustained-release recombinant human GH formulation, LB03002, has been recently developed, with pharmacokinetics and pharmacodynamic activity appropriate for once-weekly administration. LB03002 is a long-acting GH that is administered once a week by sc injection.
GH formulations with sustained release have been developed and tested in growing children (4) and in adults (5-7) with GHD, although none has yet been approved for adult GHD. Nutropin depot was the only sustained-release GH product marketed for long-term treatment of growth failure in pediatric patients (4) . It showed clinical benefit comparable to daily GH in adults but was not approved or marketed for this indication because the compound was withdrawn in 2004 (8) .
LB03002 is a new sustained-release formulation consisting of microparticles containing GH incorporated into sodium hyaluronate and dispersed in an oil base of medium-chain triglycerides. The pharmacokinetic and pharmacodynamic properties of this compound have been tested in pediatric (9) and adult (10) patients with GHD. No evident safety concerns emerged with LB03002.
On the background of the pharmacokinetic studies, a double-blind, placebo-controlled clinical study in adult GHD patients has been carried out with the once-weekly sustained-release GH formulation, LB03002. The present report documents the efficacy and safety of LB03002 administered once weekly for 26 wk in adult patients with GHD.
Patients and Methods

Study design and patients
This study was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki with appropriate regulatory and ethical approval. Written informed consents were signed by subjects. A total of 152 adult GHD patients were randomized with 2:1 active vs. placebo arms, with stratification by region, and within region by gender and GHD onset type. The primary efficacy endpoint was to demonstrate a clinical superiority of LB03002 over placebo in terms of improvement in fat mass (FM) in adult patients with GHD.
Patients with a confirmed diagnosis of GHD established by either a negative response to a GH stimulation test, with a peak cutoff at 3 g/liter for insulin tolerance test and 5 g/liter for the arginine-GHRH test, or the presence of at least three other pituitary hormone deficiencies participated in the study. Mean body mass index was 27.9 kg/m 2 in both sexes. GHD could be either adult onset (AO) or childhood onset (CO) and idiopathic or secondary to pituitary disease. IGF-I SD score (SDS) had to be less than or equal to Ϫ1 with no exposure to exogenous GH within the previous 6 months. Patients were excluded if they had evidence of any contraindications to GH treatment, were unable to undergo dual-energy x-ray absorptiometry (DXA) or were using weight-reducing drugs or appetite suppressants. Patients with overt diabetes mellitus [fasting glucose level Ͼ160 mg/dl (8.88 mmol/liter)] or impaired glucose tolerance [fasting glucose level Ͼ100 mg/dl (5.55 mmol/liter)] and/or a history of impaired glucose tolerance were excluded.
Study drug administration and dose selection
The test product was supplied in powder form and administered as a homogeneous suspension with a GH concentration of 10 mg/ml after reconstitution with medium-chain triglyceride. LB03002 contains a recombinant human GH manufactured in genetically engineered yeast cells (Saccharomyces cerevisiae). The LB03002 dose was chosen based on current guidelines for GH replacement for adults with GHD, and previous studies that employed a dose titration approach (11) (12) (13) (14) (15) (16) . Starting GH dose was 2 mg/wk (3 mg/wk for females on oral estrogen replacement), and the LB03002 dose was gradually adjusted to achieve a serum IGF-I value between Ϫ0.5 and ϩ1.5 SDS at 4 Ϯ 1 d after dosing, which was previously shown to be the time of median serum IGF-I level (10) .
Changes in dose were carried out after wk 2, 6, 10, 14, and 20, with each increase being 1 mg/wk (or 1.5 mg/wk for females on oral estrogen) and each decrease being 0.5 mg/wk for all patients with the maximum allowed dose of 7 mg/wk (or 10.5 mg/wk for females on oral estrogen). All dose adjustments were determined by a designated medical expert at the central laboratory. To maintain blinding of the treatment assignment, placebo doses were adjusted to imitate the dose adjustment schedule of the LB03002 group. Dose reductions or treatment interruptions could take place at any time during the study according to the investigators' clinical judgment based on side effects and/or abnormal laboratory findings including fasting glucose, insulin, and glycosylated hemoglobin (HbA1c).
Other pituitary hormone replacement
At screening, adrenal function was evaluated by an ACTH stimulation test in all patients who were not receiving glucocorticoid replacement. During the 3 months before study entry and throughout the study, temporary adjustment of glucocorticoid replacement therapy, as appropriate, was permitted. Other hormone replacement therapies had to be adequate and stable for at least 3 months before study entry. For female patients receiving estrogen, the same route of treatment had to be maintained throughout the study.
Efficacy assessments
Body composition was measured by DXA (GE Medical Systems Lunar, Waukesha, WI; or Hologic DXA, Bedford, MA), including FM and lean body mass (LBM). In addition, total trunk fat was calculated as FM Ϫ (total arm fat ϩ total leg fat ϩ head fat) (8) . Percent body fat was defined as (total body fat/total body mass) ϫ 100, percent trunk fat as (total trunk fat/total trunk mass) ϫ 100 [where total trunk mass ϭ total body mass Ϫ (total arm mass ϩ total leg mass ϩ head mass)], and percent reduction in trunk fat as [trunk fat (baseline) Ϫ trunk fat (end of study)]/ trunk fat (baseline) ϫ 100. All DXA readings were carried out at a central facility (DXA Resource Group, Westborough, MA), with quality control by means of phantom scans.
Serum IGF-I and IGF-binding protein (IGFBP)-3 concentrations were measured at a central laboratory (Medizinische Klinik Innenstadt, Munich, Germany) using Siemens Immulite chemiluminescence assays. Study sites were not notified of the serum IGF-I and IGFBP-3 results to maintain blinding, and only the medical expert from the central laboratory knew the results to enable study medication dose changes.
GH and S. cerevisiae at baseline, inclusion, and endpoint visits. Glucose homeostasis was assessed from fasting glucose and insulin and HbA1c concentrations. Thyroid function was assessed by measurement of free T 3 , free T 4 , and TSH. Blood samples were taken before patients took the study drug and during the assigned visits. To diagnose adrenal insufficiency, the standard short ACTH (250 g) stimulation test was performed at screening and at wk 26 in all patients not on glucocorticoid replacement therapy. Anti-GH antibodies were quantified by a radioprecipitation assay. Because GH protein was derived from S. cerevisiae, anti-yeast antibodies were determined by a solid-phase enzyme immunoassay system. Local tolerability was assessed by the investigators and patients as injection site reactions.
Statistical analysis
Statistical analysis was carried out using analysis of covariance (ANCOVA), with country, gender, onset type, and baseline FM and IGF-I concentration as covariates. Interactions between treatment and each of the covariates were removed from the model unless they were statistically significant (P Ͻ 0.05). In addition to P values, least square (LSq) means for the two treatments and differences between treatments were estimated from the ANCOVA, together with 95% confidence interval (CI). Continuous data were summarized by means of summary statistics, and categorical data were summarized by means of counts and percentages.
Results
Study population
A total of 151 patients were evaluated, comprising 101 patients treated with LB03002 and 50 with placebo; data were excluded from the dataset for one randomized patient who never received study medication before withdrawing consent. Baseline demographic and diagnostic data are presented in Table 1 . There were no evident differences between the two treatment groups in demographic characteristics. There were more patients with AO GHD (71.5%) than CO GHD (28.5%).
The baseline clinical diagnoses showed that the most common cause of GHD was nonsecreting pituitary adenoma (31.1%), followed by secreting pituitary adenoma (17.2%), idiopathic GHD (17.2%; 23 of 26 idiopathic GHD patients were CO), and craniopharyngioma (13.9%). For the disorder leading to GHD, 63.6% had undergone surgery, 29.1% had radiation therapy, 27.8% had received no treatment, and 7.9% had other treatment. Median time since diagnosis was similar for the LB03002 group (12.1 yr) and the placebo group (12.3 yr) and was similar for males and females (12.1 and 12.5 yr, respectively). For patients with AO GHD, median time since diagnosis was 9.8 yr, whereas for patients with CO GHD, median time since diagnosis was 20.1 yr.
The average final weekly dose of LB03002 was 4.31 
IGF-I and IGFBP-3 concentrations
The individual patient IGF-I values throughout the study are shown in Fig. 1 for each treatment group. With the dose titration algorithm used, IGF-I SDS mean (SD) increased in the LB03002 group from a baseline mean of Ϫ4.91 (2.93) to Ϫ0.43 (1.98) at study endpoint, with no change in the placebo group [Ϫ4.52 (2.64) to Ϫ4.27 (2.65)], demonstrating a statistically significant (P Ͻ 0.001) treatment effect. The IGF-I SDS increase in the treatment group was progressive and smooth, with only one patient exceeding ϩ2 SDS at wk 26. Not unexpectedly, the lowest IGF-I concentrations were seen in females on oral estrogen in both the LB03002 and placebo groups.
Overall at baseline, mean (SD) IGFBP-3 concentration was slightly lower in the LB03002 group [2546.0 (1212.4) g/liter] than in the placebo group [2883.0 (1244.7) g/liter]. At wk 26, mean serum IGFBP-3 level was increased to 4043.7 (1151.7) g/liter in the LB03002 group (P Ͻ 0.0001) and decreased to 2757.0 (1126.3) g/liter in the placebo group. Overall, the difference in the change of IGFBP-3 SDS from visit 2 to visit 8 was statistically significant between the LB03002 and placebo groups (P Ͻ 0.0001).
Body composition parameters
DXA body composition baseline values and changes from baseline to endpoint are presented in Table 2 Changes in trunk fat were quantitatively comparable to those seen in overall FM: Ϫ1.05 (1.49) kg in the LB03002 group compared with Ϫ0.05 (1.57) kg in the placebo group (P Ͻ 0.001), with a LSq mean treatment difference of 1.032 kg (95% CI ϭ Ϫ1.560 to Ϫ0.515). When calculated as percent change from baseline, the mean (SD) reduction in trunk fat was 7.65 (10.67)% in the treatment group compared with a mean increase of 0.59 (14.05)% in the placebo group (P Ͻ 0.001). There was also a statistically significantly greater decrease from baseline to endpoint in percent trunk fat in the LB03002 compared with the placebo group [LB03002, Ϫ2.69 (2.77)%, vs. placebo, Ϫ0.43 (3.48)%; P Ͻ 0.001]. There were no statistically significant treatment differences in lipid parameters between LB03002 and placebo in the overall analysis (P Ͼ 0.05). 
Safety
Adverse events
Overall, 147 patients (96.7%) completed the study, comprising 100 (99.0%) of the LB03002 group and 47 (94.0%) of the placebo group; discontinuation was due to adverse events for one patient in the LB03002 group (progression of an intracranial tumor) and three patients in the placebo group (hypotonia, mild acute renal failure, and thrombophlebitis). The progression of intracranial tumor and the thrombophlebitis were, respectively, considered possibly and probably related to the study drug; the hypotonia and mild acute renal failure were not reported as serious or to be related to study drug. Table 3 presents the adverse events that occurred during the study period with incidence higher than 5%, listed by MedDRA System Organ Class and preferred terms. The overall adverse event rate was similar in both treatment groups (P ϭ 1.000), with the majority reported as being not related to the study drug and most classified as mild to moderate. Adverse reactions reported as possibly, probably, or definitely related to study drug were 37.3% in the LB03002 group (the other 33.3% reported as not related or unlikely related) and 24.5% in the placebo group (the other 44.8% reported as not related or unlikely related). In addition, carpal tunnel syndrome was reported in 2.9% (three patients: one not related and two possibly/ probably related) of LB03002-treated patients vs. 0.0% in the placebo group. There were three adverse events related to tumors, which occurred in the LB03002 group: one case of basal cell carcinoma (reported as not related), one case of lipoma (reported as not related), and one case of progression of an intracranial neurofibroma (reported as possibly related); the patient with the neurofibroma was the only one in the LB03002 group to withdraw from the Percent reduction in trunk fat is defined as (baseline trunk fat Ϫ endpoint trunk fat/baseline trunk fat) ϫ 100. study. The incidence of serious adverse events did not differ between treatment groups (P ϭ 1.000). Mean free T 3 levels at baseline were similar for both treatment groups [LB03002, 279.2 pg/dl (4.3 pmol/liter); placebo, 292.2 pg/dl (4.5 pmol/liter)] and increased by 27.3 pg/dl (0.42 pmol/liter) in the LB03002 group (P ϭ 0.419) and decreased by 9.1 pg/dl (0.14 pmol/liter) in the placebo group from baseline to wk 26. Mean free T 4 at baseline was similar for LB03002 and placebo groups [1.32 ng/dl (17.0 pmol/liter) and 1.26 ng/dl (16.2 pmol/ liter)], and there was a decrease in the LB03002 group by 0.22 ng/dl (2.8 pmol/liter) vs. an increase in the placebo group by 0.01 ng/dl (0.19 pmol/liter). A shift from normal to low serum free T 4 was reported for 20 patients in the LB03002 group, and there was a statistically significant (P ϭ 0.006) difference between treatment groups in incidence of abnormal values at wk 26. Mean TSH at baseline was similar for LB03002 and placebo groups (0.61 and 0.76 U/ml) and increased in both groups from baseline to wk 26 (LB03002: by 0.07 U/ml; placebo: by 0.16 U/ ml). Mean TSH increase in LB03002 group was not statistically significant (P ϭ 0.09). Mean serum cortisol was 11.2 g/dl (0.31 mol/liter) and 10.8 g/dl (0.30 mol/ liter) at baseline and decreased slightly in the LB03002 group [2.17 g/dl (0.06 mol/liter)] vs. a slight increase in the placebo group [0.36 g/dl (0.01 mol/liter)]. In the LB03002 group, two patients at screening, two patients at wk 14, and one patient at wk 26 had cortisol levels below 18 g/dl (0.50 mol/liter) at 60 min after the ACTH stimulation test, and one patient in the placebo group had cortisol levels below 18 g/dl (0.50 mol/liter) at wk 14 and none at screening and wk 26.
FIG. 2. Changes in body FM
Injection site reactions
Injection site reactions were reported by 39.2% of LB03002-treated patients and 32.7% of placebo patients; however, most were considered mild, and all resolved. There were no discontinuations due to injection site reactions and none reported as adverse events. The majority of patients subjectively assessed discomfort at injection site as none (at least 46.9% of each group at each visit) or mild (at least 28.4% of each group at each visit).
Glucose homeostasis
There were no significant changes from baseline to endpoint in mean fasting glucose, insulin, or HbA1c concentrations in either the LB03002 or the placebo group (Table  4) . There were no adverse event of diabetes reported, although two patients in the LB03002 group and one patient in the placebo group had fasting glucose values over 126 mg/dl (7.0 mmol/liter), i.e. above the diabetes mellitus threshold (17). The incidence of impaired glucose toler- 
Antibody assessments
None of the patients was positive for antibodies against GH at baseline, and four patients (3.9%) were positive at endpoint in the LB03002 group. No patient in the placebo group was positive for GH antibodies at any time point. In the LB03002 group, three patients were positive for antibodies to S. cerevisiae at both baseline and endpoint. This might be because subjects have been exposed at baseline to S. cerevisiae, which is a similar yeast strain to Baker's yeast. In the placebo group, no patients were positive at baseline, but three patients were positive at endpoint. No differences in efficacy and safety were noted for patients with positive antibody to GH or to S. cerevisiae when compared with the remainder of the cohort.
Discussion
In the present study, we report the 6-month efficacy and safety profile in adult GHD patients of a new sustainedrelease GH formulation, LB03002. In conclusion, this study has demonstrated significant reduction in FM, thereby fulfilling the primary endpoint. Based on phase II data in adults and experience in children with GHD (9, 10), injections were given once per week. The present study protocol used an LB03002 dose titration approach based on target IGF-I SDS in the range of Ϫ0.5 to ϩ1.5. With this dose algorithm, a progressive normalization of IGF-I SDS was obtained during the 6 months, without undue elevations. The starting dose was low at 2 mg/wk (3 mg/wk for females on oral estrogen), and the average final dose was 4.31 mg/wk for males and 4.34 mg/wk for females (6.45 mg/wk for females on oral estrogen) at wk 26. To reach the desired IGF-I SDS range, a 30% higher final dose was needed in females taking oral estrogen, similar to previous data with daily GH (11) . A past pharmacokinetic/pharmacodynamic study has shown that when the dose of LB03002 was seven to eight times that of the daily GH formulation, the maximum serum concentration (C max ) with LB03002 was only doubled, and the dosenormalized area under the curve was proportional to the dose, which was not different between daily GH and LB03002 formulations (10) .
The effects of the LB03002 on IGF-I level were accompanied by the expected changes in body composition in adult patients. After 6 months of treatment, the LB03002 group showed a 1-kg decrease in FM and 2-kg increase in LBM, and these changes were significant compared with placebo (P ϭ 0.0005). Patients in the present study had a mean BMI of 27.9 kg/m 2 . In fact, the GH-induced decrease in trunk fat averaged 1 kg as well, indicating that the treatment effect on fat tissue occurred almost entirely on abdominal fat. Expressed in percentage terms, this was an 8.5% decrease in trunk fat compared with a 0.1% increase in the placebo group (LSq mean treatment difference was 8.7%, with 95% CI ϭ 4.58 -12.84). There were no statistically significant treatment differences in lipid parameters between LB03002 and placebo in the overall analysis (P Ͼ 0.05).
The 6-month safety profile of LB03002 did not demonstrate any unexpected events. Overall, total incidence of adverse events did not differ between LB03002 and placebo, although those typically occurring at the start of GH replacement were, as expected, more frequent in the LB03002 group. The 11␤-hydroxysteroid dehydrogenase type 1 enzyme activity is enhanced in GHD, thus exposing the tissues to more cortisol, whereas GH replacement inhibits the type 1 shuttle (18). GH replacement increases conversion of T 4 to T 3 and reduces the conversion of T 4 to rT 3 (18) . Therefore, careful monitoring of thyroid function was required throughout. The effect of sustainedrelease GH administration on glucose control was care- fully monitored. In addition, there were no persistent adverse events typical of acromegaly seen during the 6-month treatment with LB03002. Anti-GH antibodies were detected in 3.9% of GHD children treated with LB03002 and also compatible with other daily injectable somatropin preparations (19, 20) . The GH protein of LB03002 is produced in yeast, and the genetic modification of the yeast cells and the purification of the GH molecule may produce a spectrum of proteins different from that of naturally occurring S. cerevisiae antigens. However, positive antibody titers were observed in patients at both baseline and during treatment, suggesting that these findings were not specific for the LB03002-derived proteins (20, 21) .
This study has provided evidence that GH replacement in adult patients with GHD can be successful with the once-weekly sustained release formulation. The LB03002 was effective at a relatively low dose and displayed a reassuring safety profile.
